Taro Pharmaceutical is introducing its first specialty generic, a therapeutic equivalent to Ferriprox. The Hawthorne, N.Y.-based company’s deferiprone is an iron chelator indicated to treat patients with transfusional iron overload due to thalassemia syndromes whose current chelation therapy is inadequate.
Though thalassemia syndromes are relatively rare in the United States, they are one of the world’s most common autosomal recessive disorders, the company said. Roughly 1 in 100,000 people are affected by them.
Taro said that its generic would be dispensed exclusively via BioPlus Specialty Pharmacy.